The GLP-1 weight-management wave has put two names in front of every medspa owner — semaglutide and tirzepatide — usually arriving as patient requests shaped by brand recognition and social media rather than any understanding of the underlying drugs. For an owner deciding whether and how to offer weight-management services, the useful question isn't which is clinically "better" in the abstract, but how each fits a medspa offering and what the two share in terms of compliance burden.
This is general education for owners, not medical advice. GLP-1 weight-management services involve significant regulatory and sourcing complexity; structure any offering with your medical director and counsel.